Neutralizing anti-IFNβ antibodies: clarity and confusion

Boz C. , Oger J. , Gibbs E. , Grossberg SE and the Neurologists of the UBC MS Clinic. Reduced effectiveness of long-term interferon-β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler 2007; 13: 1127—37.

Goodin DS , Frohman EM , Hurwitz B. et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 977—84.

Pachner A. , Dail D. , Pak E. , Narayan K. The importance of measuring IFNß bioactivity: monitoring in MS patients and the effect of anti-IFNß antibodies. J Neuroimmunol 2005; 166: 180—8.

Pachner A. , Narayan K. , Pak E. Multiplex analysis of expression of three IFNß-induced genes in antibody-positive MS patients. Neurology 2006; 66: 444—6.

Sorensen PS , Ross C. , Clemmesen KM et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184—91.

Malucchi S. , Sala A. , Gilli F. et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004; 62: 2031—37.

Soelberg Sorensen P , Koch-Henriksen N. , Ross C. , Clemmesen KM , Bendtzen K. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33—9.

Richert ND , Zierak MC , Bash CN , Lewis BK , McFarland HF , Frank JA MRI and clinical activity in MS patients after terminating treatment with interferonβ. Multiple Sclerosis 2000; 6: 86—90.

Rudick R. Biologic impact of interferon antibodies, and complexities in assessing their clinical significance. Neurology 2003; 61: S29—S32.

Filippini G. , Munari L. , Incorvaia B. et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003; 361: 545—52.

Rudick RA , Simonian NA , Alam JA et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1206—8.

Sorensen PS , Deisenhammer F. , Duda P. et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817—27.

Oger J. (Guest Editor) Clarifying the issues on antibodies to interferon in MS: Views from industry and four academics. Mult Scler 2007; 13 (Suppl 1): s5—s62.

Farrell RA , Giovannoni G. Measuring and management of Antiferon Beta Antibodies in subjects with Multiple Sclerosis. Mult Scler 2007; 13: 567—577.

Pachner AR An improved ELISA for screening for neutralizing anti-IFNß antibodies in MS patients. Neurology 2003; 61: 1444—6.